Another investor attack launched against a pharma patent at the PTAB; and Kyle Bass is not involved
An IPR has been filed against an Allergan patent by an investment firm in a move that will heighten fears in the life sciences industries about the potential damage the PTAB process could do to their IP rights. The latest move comes after two…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.